Sign in
BLCM Stock Price, Chart, Stats & News
Bellicum Pharmaceuticals, Inc.
Save
Bellicum Pharmaceuticals, Inc. (BLCM) does not currently pay a dividend.
778,326
Market cap
–
Current P/E
–
Forward P/E
BLCM chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 100.00% |
Operating margin | -1798.73% |
Pretax margin | -1664.73% |
Net margin | -1664.87% |
Effective tax rate | -0.01% |
ROA | -104.83% |
ROE | -189.12% |
D/E | – |
Interest coverage ratio | -586543.48x |
BLCM valuation
P/E | – |
P/S | 0.52x |
P/B | 1.14x |
P/CF | -0.09x |
P/FCF | -0.03x |
P/OCF | -0.09x |
PEG | -0.00x |
EV multiple | -0.84x |
About
Bellicum Pharmaceuticals, Inc. (BLCM) operates as a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing innovative cellular immunotherapies. Its primary objective is to combat blood cancers and solid tumors across domestic and global markets. Among its pipeline of experimental therapies are two key GoCAR-T candidates currently undergoing Phase 1/2 clinical evaluations.
Similar securities
Based on sector and market capitalization
Report issue